Focus: Cocrystal Pharma is a public antiviral-focused biopharmaceutical company developing treatments for infectious diseases and neurology. The company operates at a pre-revenue stage with a pipeline of early-stage programs in influenza, hepatitis C, and norovirus.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Cocrystal Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Cocrystal Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Cocrystal Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate - simplywall.st
We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate simplywall.st
Cocrystal's norovirus pill gets FDA fast track amid 685M yearly cases - Stock Titan
Cocrystal's norovirus pill gets FDA fast track amid 685M yearly cases Stock Titan
Cocrystal Pharma Wins FDA Fast Track for Norovirus Drug - TipRanks
Cocrystal Pharma Wins FDA Fast Track for Norovirus Drug TipRanks
FDA Fast Track backs Cocrystal (Nasdaq: COCP) oral norovirus antiviral CDI-988 - Stock Titan
FDA Fast Track backs Cocrystal (Nasdaq: COCP) oral norovirus antiviral CDI-988 Stock Titan
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive - GlobeNewswire
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive GlobeNewswire
Cocrystal Pharma Reports 2025 Financial Results and Advances Norovirus and Influenza Antiviral Drug Pipeline - Minichart
Cocrystal Pharma Reports 2025 Financial Results and Advances Norovirus and Influenza Antiviral Drug Pipeline Minichart
Showing 6 of 8 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo